Licensing Negotiations--and Stale Cookies

Gordon, Maxwell
December 2004
Chemical Heritage;Winter2004/2005, Vol. 22 Issue 4, p12
Provides information on the licensing negotiations of Bristol-Myers in Japan and Russia during the 1970s. Significance of scientist managers to the pharmaceutical industry; Details of the negotiations of Bristol-Myers with Microbial Chemistry Research Foundation in Tokyo, Japan and Nippon Kayaku on the cancer antibiotic bleomycin; Comparison between Soviet and Japan negotiators.


Related Articles

  • Exelixis Gets $195M Up Front in BMS Deal.  // Bioworld Week;12/22/2008, Vol. 16 Issue 51, p2 

    The article reports on the $195 million up front deal obtained by Exelixis Inc. from Bristol-Myers Squibb Co. (BMS) for its rights to cancer programs in the U.S. The deal makes BMS to pay $195 million up front for the program rights with additional $45 million license payments in 2009. Under the...

  • COMPANY SPOTLIGHT - Bristol-Myers Squibb Company.  // PharmaWatch: CNS;May2009, Vol. 8 Issue 5, p23 

    The article presents a corporate profile for Bristol-Myers Squibb Co. (BMS) in the U.S. BMS is involved in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company engages in research collaborations and...

  • AUREUS PHARMA RENEWS/EXPANDS AURSCOPE DB LICENSING.  // Worldwide Databases;Dec2007, Vol. 19 Issue 12, p7 

    The article reports that Aureus Pharma, a provider of knowledge management solutions has announced that Bristol-Myers Squibb Co., has renewed its license to Aureus' AurSCOPE GPCR and also licensed its AurSCOPE Kinase and Ion Channel Knowledge databases. Jason Theodosiou, chief executive officer...

  • PDL Could Get $1B from BMS for Two Antibodies.  // Bioworld Week;8/25/2008, Vol. 16 Issue 34, p1 

    The article reports on the agreement signed between PDL BioPharma Inc. and Bristol-Myers Squibb Co. (BMS) for the latter to have the rights to commercialize and develop two antibodies produced by the former. Accordingly, BMS paid over $710 million for the deal, which covers the Phase I anti-CS1...

  • Pharma.  // ICIS Chemical Business Americas;9/11/2006, Vol. 270 Issue 9, p32 

    The article presents news briefs related to the pharmaceutical industry. Bristol-Myers Squibb has lowered its previously disclosed full year 2006 earnings guidance. Eli Lilly has entered a license agreement with privately held biopharmaceutical company Anthera. Pfizer has won a patent challenge...

  • ImClone: astute new strategy for Erbitux.  // PharmaWatch: Cancer;March 2003, Vol. 2 Issue 3, p17 

    Reports on the plan of Imclone Systems Inc. and Bristol-Myers Squibb Co. to increase the availability of its erbitux drug to cancer patients in the U.S. Description of erbitux; Indication for the drug; Disagreements over the marketing of the medication in North America.

  • Pharma considers personalization, competition into drug costs. Kaltwasser, Jared // njbiz;2/6/2012, Vol. 25 Issue 6, p16 

    The article reports on the efforts of several pharmaceutical firms like Bristol-Myers Squibb and Sanofi to launch cancer drugs with costs in a similar price range. M.D. Becker Partners founder Michael D. Becker said higher prices should not be qualified as a negative trend. He added that the...

  • Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug. Shrine, Jim // BioWorld Today;9/25/2007, Vol. 18 Issue 186, p1 

    The article reports that the shares of Sonus Pharmaceuticals Inc. has lost more than 80% of their value when its product Tocosol Paclitaxel failed in its Phase III trial in patients with metastatic breast cancer. The trial, which was aimed to show that Tocosol provided noninferior objective...

  • Melanoma Combo Aces Test. Investor's Business Daily // Investors Business Daily;6/3/2014, pA01 



Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics